Kissling, EstherHooiveld, MariëtteMartínez-Baz, IvánMazagatos, ClaraWilliam, NaomaVilcu, Ana-MariaKooijman, Marjolein NIlić, MajaDomegan, LisaMachado, Ausendade Lusignan, SimonLazar, MihaelaMeijer, AdamBrytting, MiaCasado, ItziarLarrauri, AmparoMurray, Josephine-L KBehillil, Sylviede Gier, BrechjeMlinarić, IvanO'Donnell, JoanRodrigues, Ana PaulaTsang, RubyTimnea, Oliviade Lange, MaritRiess, MaximilianCastilla Catalán, JesúsPozo Sanchez, FranciscoHamilton, MarkFalchi, AlessandraKnol, Mirjam JKurečić Filipović, SanjaDunford, LindaGuiomar, RaquelCogdale, JadeCherciu, CarmenJansen, TessaEnkirch, TheresaBasile, LucaConnell, JeffGomez, VerónicaSandonis-Martin, VirginiaBacci, SabrinaRose, Angela McPastore Celentano, LuciaValenciano, MartaI-MOVE-COVID-19ECDC primary care study teamsConde-San Román, PatriciaCasas Flecha, InmaculadaOliva Dominguez, Jesus AngelDelgado-Sanz, Concepcion2022-11-152022-11-152022-05Euro Surveill. 2022 May;27(21):2101104.http://hdl.handle.net/20.500.12105/15149Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19Delta variantEuropeSARS-CoV-2Multicentre studyTest-negative designVaccine effectivenessCOVID-19Influenza VaccinesInfluenza, HumanCOVID-19 VaccinesEuropeHumansPrimary Health CareSARS-CoV-2VaccinationAttribution-NonCommercial-NoDerivatives 4.0 Internacional356209972721210110410.2807/1560-7917.ES.2022.27.21.21011041560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access